Evotec SE (NASDAQ:EVO) Short Interest Up 104.3% in November

Evotec SE (NASDAQ:EVO) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 449,700 shares, an increase of 104.3% from the October 31st total of 220,100 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average daily volume of 195,200 shares, the days-to-cover ratio is currently 2.3 days.

Evotec Trading Up 1.5 %

Shares of NASDAQ:EVO traded up $0.07 during trading on Thursday, hitting $4.83. The company’s stock had a trading volume of 145,857 shares, compared to its average volume of 134,367. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43. Evotec has a fifty-two week low of $2.85 and a fifty-two week high of $12.00. The stock’s 50-day moving average price is $3.90 and its two-hundred day moving average price is $4.19.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Evotec during the 2nd quarter worth approximately $87,000. Cetera Advisors LLC acquired a new stake in shares of Evotec during the 1st quarter worth approximately $188,000. Clear Harbor Asset Management LLC bought a new position in Evotec in the 3rd quarter worth approximately $104,000. DCF Advisers LLC grew its holdings in Evotec by 140.5% in the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after buying an additional 67,156 shares in the last quarter. Finally, Mediolanum International Funds Ltd bought a new position in Evotec in the 3rd quarter worth approximately $512,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Evotec in a research note on Thursday, November 7th. Jefferies Financial Group downgraded Evotec from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $8.70 to $3.80 in a report on Monday, October 7th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Evotec from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Evotec has an average rating of “Hold” and an average target price of $5.93.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.